Clinical

Dataset Information

0

Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy: A placebo-controlled double blind randomized Phase II study (The GONE Study)


ABSTRACT: Interventions: FOLFOX4(L-OHP85mg/m2, l-LV100mg/m2x2, 5FU400mg/m2(bolus)x2, 5FU600mg/m2x2(civ)) or mFOLFOX6(L-OHP85mg/m2, l-LV200mg/m2, 5FU400mg/m2(bolus), 5FU240mg/m2(civ)).Cycles of chemotherapy are given every 2 weeks until PD or unacceptable toxicity occurred. Goshajinkigan(GJG) is given orally at a dose of 2.5 g three times a day for 26 weeks starting on the day of L-OHP infusion. FOLFOX4(L-OHP85mg/m2, l-LV100mg/m2x2, 5FU400mg/m2(bolus)x2, 5FU600mg/m2x2(civ)) or mFOLFOX6(L-OHP85mg/m2, l-LV200mg/m2, 5FU400mg/m2(bolus), 5FU240mg/m2(civ)).Cycles of chemotherapy are given every 2 weeks until PD or unacceptable toxicity occurred. Placebo is given orally at a dose of 2.5 g three times a day for 26 weeks starting on the day of L-OHP infusion. Primary outcome(s): The incidence of peripheral neurotoxicity ≥grade 2 after eight cycles of chemotherapy. Study Design: Parallel Randomized

DISEASE(S): Colorectal Cancer

PROVIDER: 2617692 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2619165 | ecrin-mdr-crc
2013-01-01 | GSE41998 | GEO
2024-10-21 | GSE186299 | GEO
| 2616452 | ecrin-mdr-crc
2013-01-01 | E-GEOD-41998 | biostudies-arrayexpress
2022-07-11 | E-MTAB-11901 | biostudies-arrayexpress
| 2610116 | ecrin-mdr-crc
| 2456506 | ecrin-mdr-crc
2010-05-25 | GSE21974 | GEO
| 2573933 | ecrin-mdr-crc